Your browser doesn't support javascript.
loading
Metabolically Stable Anomeric Linkages Containing GalNAc-siRNA Conjugates: An Interplay among ASGPR, Glycosidase, and RISC Pathways.
Kandasamy, Pachamuthu; Mori, Shohei; Matsuda, Shigeo; Erande, Namrata; Datta, Dhrubajyoti; Willoughby, Jennifer L S; Taneja, Nate; O'Shea, Jonathan; Bisbe, Anna; Manoharan, Rajar M; Yucius, Kristina; Nguyen, Tuyen; Indrakanti, Ramesh; Gupta, Swati; Gilbert, Jason A; Racie, Tim; Chan, Amy; Liu, Ju; Hutabarat, Renta; Nair, Jayaprakash K; Charisse, Klaus; Maier, Martin A; Rajeev, Kallanthottathil G; Egli, Martin; Manoharan, Muthiah.
Afiliación
  • Kandasamy P; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Mori S; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Matsuda S; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Erande N; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Datta D; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Willoughby JLS; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Taneja N; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • O'Shea J; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Bisbe A; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Manoharan RM; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Yucius K; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Nguyen T; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Indrakanti R; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Gupta S; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Gilbert JA; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Racie T; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Chan A; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Liu J; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Hutabarat R; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Nair JK; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Charisse K; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Maier MA; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Rajeev KG; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
  • Egli M; Department of Biochemistry, School of Medicine, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Manoharan M; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, United States.
J Med Chem ; 66(4): 2506-2523, 2023 02 23.
Article en En | MEDLINE | ID: mdl-36757090
ABSTRACT
Conjugation of synthetic triantennary N-acetyl-d-galactosamine (GalNAc) to small interfering RNA (siRNA) mediates binding to the asialoglycoprotein receptor (ASGPR) on the surface of hepatocytes, facilitating liver-specific uptake and siRNA-mediated gene silencing. The natural ß-glycosidic bond of the GalNAc ligand is rapidly cleaved by glycosidases in vivo. Novel GalNAc ligands with S-, and C-glycosides with both α- and ß-anomeric linkages, N-glycosides with ß-anomeric linkage, and the O-glycoside with α-anomeric linkage were synthesized and conjugated to siRNA either on-column during siRNA synthesis or through a high-throughput, post-synthetic method. Unlike natural GalNAc, modified ligands were resistant to glycosidase activity. The siRNAs conjugated to newly designed ligands had similar affinities for ASGPR and similar silencing activity in mice as the parent GalNAc-siRNA conjugate. These data suggest that other factors, such as protein-nucleic acid interactions and loading of the antisense strand into the RNA-induced silencing complex (RISC), are more critical to the duration of action than the stereochemistry and stability of the anomeric linkage between the GalNAc moiety of the ligand conjugated to the sense strand of the siRNA.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Complejo Silenciador Inducido por ARN / Receptor de Asialoglicoproteína / ARN Interferente Pequeño / Galactosamina Límite: Animals Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Complejo Silenciador Inducido por ARN / Receptor de Asialoglicoproteína / ARN Interferente Pequeño / Galactosamina Límite: Animals Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos